TScan Therapeutics (TCRX) Revenue (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Revenue of $982000.0 for Q1 2026, down 54.77% year-over-year from $2.2 million in Q1 2025, and down 61.75% quarter-over-quarter from $2.6 million in Q4 2025.
TScan Therapeutics (TCRX) Revenue (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Revenue for 7 consecutive years, with $982000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue fell 54.77% year-over-year to $982000.0; the TTM figure through Mar 2026 stood at $9.1 million (up 106.65% YoY), while the FY2025 annual figure was $10.3 million, up 266.65% from the prior year.
- Revenue retreated to $982000.0 in Q1 2026 per TCRX's latest filing, from $2.6 million in the prior quarter.
- Across five years, Revenue topped out at $7.2 million in Q4 2023 and bottomed at $536000.0 in Q2 2024.
- Historically, Revenue has averaged $2.8 million across 5 years, with a median of $3.0 million in 2022.
- Annual changes were most pronounced in 2024 — Revenue plunged 90.78% — and 2025, when it surged 473.88%.
- TScan Therapeutics' Revenue stood at $3.1 million in 2022, then soared by 132.99% to $7.2 million in 2023, then slumped by 90.78% to $665000.0 in 2024, then surged by 286.02% to $2.6 million in 2025, then plunged by 61.75% to $982000.0 in 2026.
- Business Quant data shows TCRX's Revenue at $982000.0 in Q1 2026, $2.6 million in Q4 2025, and $2.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.29 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.06 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 425.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 674.14 Mn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | 1.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.05 Mn |
| Mar 31, 2026 | 982,000.00 |
| Dec 31, 2025 | 2.57 Mn |
| Sep 30, 2025 | 2.51 Mn |
| Jun 30, 2025 | 3.08 Mn |
| Mar 31, 2025 | 2.17 Mn |
| Dec 31, 2024 | 665,000.00 |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 536,000.00 |
| Mar 31, 2024 | 566,000.00 |
| Dec 31, 2023 | 7.21 Mn |
| Sep 30, 2023 | 3.89 Mn |
| Jun 30, 2023 | 3.15 Mn |
| Mar 31, 2023 | 5.80 Mn |
| Dec 31, 2022 | 3.10 Mn |
| Sep 30, 2022 | 3.36 Mn |
| Jun 30, 2022 | 4.06 Mn |
| Mar 31, 2022 | 3.02 Mn |
| Dec 31, 2021 | 2.85 Mn |
| Sep 30, 2021 | 2.41 Mn |